Gilead Sciences, Inc. $GILD Shares Sold by Polaris Capital Management LLC

Key Points

• Polaris Capital Management trimmed its position in Gilead by 15.1%, selling 47,300 shares and now holds 265,100 shares worth about $32.54 million, making Gilead its 12th largest holding.
• Gilead beat quarterly expectations (EPS $1.86 vs. $1.83; revenue $7.93B vs. $7.68B) and set FY2026 guidance of 8.45–8.85 EPS, near analysts' consensus of 8.63.
• Insiders have been net sellers — including CEO Daniel O'Day's sale of 115,640 shares and 178,640 shares sold over the past 90 days — even as the company raised its quarterly dividend to $0.82 (annual $3.28, ~2.5% yield).

Polaris Capital Management LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 265,100 shares of the biopharmaceutical company's stock after selling 47,300 shares during the period. Gilead Sciences makes up about 2.7% of Polaris Capital Management LLC's portfolio, making the stock its 12th largest holding. Polaris Capital Management LLC's holdings in Gilead Sciences were worth $32,538,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in GILD. Brighton Jones LLC lifted its position in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC acquired a new stake in Gilead Sciences in the fourth quarter worth approximately $215,000. Sivia Capital Partners LLC lifted its position in Gilead Sciences by 16.8% in the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company's stock worth $464,000 after purchasing an additional 602 shares during the period. Ieq Capital LLC lifted its position in Gilead Sciences by 12.0% in the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company's stock worth $13,160,000 after purchasing an additional 12,705 shares during the period. Finally, Diversify Advisory Services LLC lifted its position in Gilead Sciences by 18.6% in the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company's stock worth $516,000 after purchasing an additional 674 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Down 2.4%

Shares of Gilead Sciences stock opened at $130.40 on Friday. The stock has a 50-day moving average price of $142.44 and a 200 day moving average price of $132.02. The company has a market cap of $161.86 billion, a P/E ratio of 19.26, a P/E/G ratio of 1.76 and a beta of 0.39. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts' consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the prior year, the business posted $1.90 earnings per share. Gilead Sciences's revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 8.63 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. Gilead Sciences's dividend payout ratio (DPR) is currently 48.45%.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of research analyst reports. Weiss Ratings restated a "buy (b)" rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. Royal Bank Of Canada upped their price target on Gilead Sciences from $118.00 to $123.00 and gave the company a "sector perform" rating in a report on Tuesday, April 7th. Rothschild & Co Redburn upped their price target on Gilead Sciences from $159.00 to $170.00 and gave the company a "buy" rating in a report on Tuesday, February 17th. Daiwa Securities Group upped their price target on Gilead Sciences from $129.00 to $161.00 and gave the company an "outperform" rating in a report on Wednesday, February 25th. Finally, Mizuho boosted their target price on shares of Gilead Sciences from $140.00 to $170.00 and gave the company an "outperform" rating in a research note on Wednesday, February 18th. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $157.35.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the transaction, the insider directly owned 120,288 shares of the company's stock, valued at approximately $18,577,278.72. This represents a 18.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Daniel Patrick O'day sold 115,640 shares of the stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the transaction, the chief executive officer directly owned 613,912 shares in the company, valued at $92,086,800. The trade was a 15.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 178,640 shares of company stock valued at $26,691,550. 0.30% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.